Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 7
2005 9
2006 6
2007 13
2008 13
2009 11
2010 12
2011 10
2012 7
2013 3
2014 13
2015 12
2016 20
2017 17
2018 13
2019 17
2020 22
2021 21
2022 14
2023 17
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Results by year

Filters applied: . Clear all
Page 1
Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez PA, Schlaepfer MI, Del Puerto-Nevado L, Aguilera O, García-García L, Galeano C, de Miguel I, Serrano-López J, Baños N, Fernández-Aceñero MJ, Lacal JC, Medico E, García-Foncillas J, Cebrián A. Rio-Vilariño A, et al. Among authors: garcia foncillas j. Br J Cancer. 2024 May;130(8):1414. doi: 10.1038/s41416-024-02667-x. Br J Cancer. 2024. PMID: 38575733 Free PMC article. No abstract available.
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez PA, Schlaepfer MI, Del Puerto-Nevado L, Aguilera O, García-García L, Galeano C, de Miguel I, Serrano-López J, Baños N, Fernández-Aceñero MJ, Lacal JC, Medico E, García-Foncillas J, Cebrián A. Rio-Vilariño A, et al. Among authors: garcia foncillas j. Br J Cancer. 2024 May;130(8):1402-1413. doi: 10.1038/s41416-024-02649-z. Epub 2024 Mar 11. Br J Cancer. 2024. PMID: 38467828 Free PMC article.
Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest.
Cenigaonandia-Campillo A, Garcia-Bautista A, Rio-Vilariño A, Cebrian A, Del Puerto L, Pellicer JA, Gabaldón JA, Pérez-Sánchez H, Carmena-Bargueño M, Meroño C, Traba J, Fernandez-Aceñero MJ, Baños-Herraiz N, Mozas-Vivar L, Núñez-Delicado E, Garcia-Foncillas J, Aguilera Ó. Cenigaonandia-Campillo A, et al. Among authors: garcia foncillas j. Mol Oncol. 2024 Feb 29. doi: 10.1002/1878-0261.13616. Online ahead of print. Mol Oncol. 2024. PMID: 38425123 Free article.
Natriuretic peptides: Another tool for the management of cancer?
Balaguer J, García-Foncillas J, Tuñón J. Balaguer J, et al. Among authors: garcia foncillas j. Crit Rev Oncol Hematol. 2024 Jan;193:104219. doi: 10.1016/j.critrevonc.2023.104219. Epub 2023 Nov 28. Crit Rev Oncol Hematol. 2024. PMID: 38029944 Review.
Cancer-Related Fatigue and Circulating Biomarkers in Breast Cancer Survivors.
García-González D, Romero-Elías M, Álvarez-Bustos A, Rosado-García S, Sánchez-López AJ, Cantos B, Maximiano C, Méndez M, Méndez-Otero M, Cebolla H, García-Foncillas J, Ruiz-Casado A. García-González D, et al. Among authors: garcia foncillas j. Biol Res Nurs. 2024 Apr;26(2):270-278. doi: 10.1177/10998004231215777. Epub 2023 Nov 10. Biol Res Nurs. 2024. PMID: 37947791
DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer.
Lacalle-Gonzalez C, Florez-Cespedes M, Sanz-Criado L, Ochieng' Otieno M, Ramos-Muñoz E, Fernandez-Aceñero MJ, Ortega-Medina L, Garcia-Foncillas J, Martinez-Useros J. Lacalle-Gonzalez C, et al. Among authors: garcia foncillas j. Biomedicines. 2023 Oct 17;11(10):2812. doi: 10.3390/biomedicines11102812. Biomedicines. 2023. PMID: 37893184 Free PMC article.
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.
Martin-Broto J, Martinez-Garcia J, Moura DS, Redondo A, Gutierrez A, Lopez-Pousa A, Martinez-Trufero J, Sevilla I, Diaz-Beveridge R, Solis-Hernandez MP, Carnero A, Perez M, Marcilla D, Garcia-Foncillas J, Romero P, Fernandez-Jara J, Lopez-Lopez D, Arribas I, Hindi N. Martin-Broto J, et al. Among authors: garcia foncillas j. Signal Transduct Target Ther. 2023 Oct 25;8(1):405. doi: 10.1038/s41392-023-01661-8. Signal Transduct Target Ther. 2023. PMID: 37875500 Free PMC article. Clinical Trial.
235 results